评估三种微小RNA组合在前列腺癌中的诊断价值：一项发现与验证研究。

Evaluation of the diagnostic value of a three-miRNA panel in prostate cancer: a discovery and validation study.

作者信息

Li Xutai, Sun Chen, Ge Zhenjian, Li Yingqi, Zhou Huimei, Wu Yutong, Lin Shengjie, Zhang Pengwu, Wu Xionghui, Lai Yongqing

机构信息

Department of Urology, Peking University Shenzhen Hospital, The Fifth Clinical Medical College of Anhui Medical University, Shenzhen, 518036, China.

Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, China.

出版信息

Discov Oncol. 2025 Apr 25;16(1):611. doi: 10.1007/s12672-025-02382-w.

DOI:10.1007/s12672-025-02382-w

PMID:40279022

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12031705/

Abstract

BACKGROUND

PSA is widely used in prostate cancer screening. However, false-positive PSA results can lead to misdiagnosis and wrong puncture biopsy, while false-negative PSA results can result in missed diagnosis and delayed treatment. There is an urgent need to find convenient, economical and non-invasive diagnostic methods to reduce the false-negative and false-positive rates of PSA. The aim of this study was to discover new miRNA panels to detect prostate cancer.

MATERIALS AND METHOD

We selected 10 miRNAs in the literature that were associated with prostate cancer. Afterwards, we measured the expression levels of these miRNAs in serum of 112 prostate cancer patients and healthy controls through a training phase and a validation phase. By plotting receiver operating characteristic curve, the miRNAs with the highest diagnosis value were chosen. Then, a set of miRNAs with the top diagnostic value was identified using stepwise logistic regression.

RESULTS

The findings showed that 5 kinds of miRNAs (let-7b-5p, miR-15a-5p, miR-133a-3p, miR-15b-5p, miR-144-3p) were abnormally expressed in the serum of prostate cancer patients. The diagnostic panel constructed with these 3 miRNAs including let-7b-5p, miR-15a-5p miR-15b-5p and which have high specificity and sensitivity in detecting prostate cancer (area under the curve (AUC) = 0.899). Furthermore, the genes FAM107A and TAF1C may be potential therapeutic targets for prostate cancer.

CONCLUSIONS

A three-microRNA panel has an important diagnostic value in prostate cancer and is expected to serve as diagnostic biomarker for prostate cancer. Furthermore, the genes FAM107A and TAF1C may be potential therapeutic targets for prostate cancer.

摘要

背景

前列腺特异性抗原（PSA）广泛应用于前列腺癌筛查。然而，PSA结果假阳性会导致误诊及错误的穿刺活检，而PSA结果假阴性则会导致漏诊和治疗延误。迫切需要找到方便、经济且无创的诊断方法以降低PSA的假阴性和假阳性率。本研究旨在发现用于检测前列腺癌的新的微小RNA（miRNA）组合。

材料与方法

我们从文献中选取了10种与前列腺癌相关的miRNA。之后，通过一个训练阶段和一个验证阶段，我们测量了这10种miRNA在112例前列腺癌患者和健康对照者血清中的表达水平。通过绘制受试者工作特征曲线，选择诊断价值最高的miRNA。然后，使用逐步逻辑回归确定一组具有最高诊断价值的miRNA。

结果

研究结果显示，5种miRNA（let-7b-5p、miR-15a-5p、miR-133a-3p、miR-15b-5p、miR-144-3p）在前列腺癌患者血清中异常表达。由let-7b-5p、miR-15a-5p、miR-15b-5p这3种miRNA构建的诊断组合在检测前列腺癌方面具有高特异性和敏感性（曲线下面积（AUC）=0.899）。此外，基因FAM107A和TAF1C可能是前列腺癌的潜在治疗靶点。